

## MD Anderson Ovarian SPORE publications – 2020

1. Arend R, Westin SN, Coleman RL. **Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review.** *Int J Gynecol Cancer.* 2020 May;30(5):684-694. doi: 10.1136/ijgc-2019-001041. Epub 2020 Feb 19. PMID: 32079709.
2. Astanehe A, Arenillas D, Wasserman WW, Leung PCK, Dunn SE, Davies BR, Mills GB, Auersperg N. **Expression of Concern: Mechanisms underlying p53 regulation of *PIK3CA* transcription in ovarian surface epithelium and in ovarian cancer.** *J Cell Sci.* 2020 Sep 11;133(17):jcs253260. doi: 10.1242/jcs.253260. PMID: 32917731.
3. Au-Yeung CL, Yeung TL, Achreja A, Zhao H, Yip KP, Kwan SY, Onstad M, Sheng J, Zhu Y, Baluya DL, Co NN, Rynne-Vidal A, Schmandt R, Anderson ML, Lu KH, Wong STC, Nagrath D, Mok SC. **ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment.** *Nat Commun.* 2020 Jul 15;11(1):3546. doi: 10.1038/s41467-020-17383-2. PMID: 32669559. PMCID: PMC7363861.
4. Bast RC Jr, Lu Z, Han CY, Lu KH, Anderson KS, Drescher CW, Skates SJ. **Biomarkers and Strategies for Early Detection of Ovarian Cancer.** *Cancer Epidemiol Biomarkers Prev.* 2020 Dec;29(12):2504-2512. doi: 10.1158/1055-9965.EPI-20-1057. Epub 2020 Oct 13. PMID: 33051337. PMCID: PMC7710577.
5. Blessing AM, Santiago-O'Farrill JM, Mao W, Pang L, Ning J, Pak D, Bollu LR, Rask P, Iles L, Yang H, Tran S, Elmir E, Bartholomeusz G, Langley R, Lu Z, Bast RC Jr. **Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition.** *Cancer.* 2020 Aug 1;126(15):3579-3592. doi: 10.1002/cncr.32985. Epub 2020 Jun 2. PMID: 32484926. PMCID: PMC7384209.
6. Cao Q, Wang W, Zhou M, Huang Q, Wen X, Zhao J, Shi S, Geng K, Li F, Hatakeyama H, Xu C, Piwnicka-Worms D, Peng W, Zhou D, Sood AK, Li C. **Induction of antitumor immunity in mice by the combination of nanoparticle-based photothermolysis and anti-PD-1 checkpoint inhibition.** *Nanomedicine.* 2020 Apr;25:102169. doi: 10.1016/j.nano.2020.102169. Epub 2020 Feb 12. PMID: 32059873. PMCID: PMC7181381.
7. Chen MM, Li J, Mills GB, Liang H. **Predicting Cancer Cell Line Dependencies From the Protein Expression Data of Reverse-Phase Protein Arrays.** *JCO Clin Cancer Inform.* 2020 Apr;4:357-366. doi: 10.1200/CCI.19.00144. PMID: 32330068. PMCID: PMC7259880.
8. Cobb LP, Sun CC, Iyer R, Nick AM, Fleming ND, Westin SN, Sood AK, Wong KK, Silva EG, Gershenson DM. **The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.** *Gynecol Oncol.* 2020 Sep;158(3):653-658. doi: 10.1016/j.ygyno.2020.06.498. Epub 2020 Jul 22. PMID: 32709538.
9. Coleman RL, Handley KF, Burger R, Molin GZD, Stagg R, Sood AK, Moore KN. **Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.** *Gynecol Oncol.* 2020 May;157(2):386-391. doi: 10.1016/j.ygyno.2020.01.042. Epub 2020 Feb 7. PMID: 32037195 *Clinical Trial.*
10. Coletta AM, Peterson SK, Gatus LA, Krause KJ, Schembre SM, Gilchrist SC, Arun B, You YN, Rodriguez-Bigas MA, Strong LL, Lu KH, Basen-Engquist K. **Diet, weight management, physical activity and Ovarian & Breast Cancer Risk in women with *BRCA1/2* pathogenic Germline gene variants: systematic review.** *Hered Cancer Clin Pract.* 2020 Mar 7;18:5. doi: 10.1186/s13053-020-0137-1. eCollection 2020. PMID: 32165993. Review. PMCID: PMC7060535.
11. Cun HT, Lu KH. **Unanswered Questions in High-Risk Women Undergoing Risk-Reducing Salpingo-oophorectomy.** *Obstet Gynecol.* 2020 Mar;135(3):495-497. doi: 10.1097/AOG.0000000000003733. PMID: 32028509.
12. Dottino JA, He W, Sun CC, Zhao H, Fu S, Rauh-Hain JA, Suidan RS, Lu KH, Giordano SH, Meyer LA. **National trends in bowel and upper abdominal procedures in ovarian cancer surgery.** *Int J Gynecol Cancer.* 2020 Aug;30(8):1195-1202. doi: 10.1136/ijgc-2020-001243. Epub 2020 Jul 2. PMID: 32616627. PMCID: PMC8328049.

13. El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, Kabil N, Ozpolat B, Calin GA, Salama SA, Abd-Allah AR, Sood AK, Lopez-Berestein G. **GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.** Cell Signal. 2020 Apr;68:109539. doi: 10.1016/j.cellsig.2020.109539. Epub 2020 Jan 11. PMID: 31935430.
14. Emborgo TS, Saporito D, Muse KI, Barrera AMG, Litton JK, Lu KH, Arun BK. **Prospective Evaluation of Universal BRCA Testing for Women With Triple-Negative Breast Cancer.** JNCI Cancer Spectr. 2020 Jan 20;4(2):pkaa002. doi: 10.1093/jncics/pkaa002. eCollection 2020 Apr. PMID: 32211581. PMCID: PMC7083268.
15. Gentry-Maharaj A, Blyuss O, Ryan A, Burnell M, Karpinskyj C, Gunu R, Kalsi JK, Dawnay A, Marino IP, Manchanda R, Lu K, Yang WL, Timms JF, Parmar M, Skates SJ, Bast RC Jr, Jacobs IJ, Zaikin A, Menon U. **Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women.** Cancers (Basel). 2020 Jul 17;12(7):1931. doi: 10.3390/cancers12071931. PMID: 32708856. PMCID: PMC7409061.
16. Guo M, Li S, Zhao X, Yuan Y, Zhang B, Guan Y. **Knockdown of Circular RNA Hsa\_circ\_0000714 Can Regulate RAB17 by Sponging miR-370-3p to Reduce Paclitaxel Resistance of Ovarian Cancer Through CDK6/RB Pathway.** Onco Targets Ther. 2020 Dec 24;13:13211-13224. doi: 10.2147/OTT.S285153. eCollection 2020. PMID: 33380810. PMCID: PMC7769200.
17. Handley KF, Sood AK. **A Solution to the Dilution: The Role for Biomarkers in Advanced Ovarian Cancer.** Clin Cancer Res. 2020 Jan 1;26(1):9-10. doi: 10.1158/1078-0432.CCR-19-3072. Epub 2019 Oct 31. PMID: 31672769. PMCID: PMC6942626.
18. Hinchcliff EM, Meyer LA, Westin SN. **Has dose-dense chemotherapy met an ICONic end?** Lancet Oncol. 2020 Jul;21(7):869-870. doi: 10.1016/S1470-2045(20)30276-X. PMID: 32615101. PMCID: PMC8284846.
19. How J, Patel A, Jazaeri A. **Immuno-oncology for Gynecologic Malignancies.** Adv Exp Med Biol. 2020;1244:149-182. doi: 10.1007/978-3-030-41008-7\_7. PMID: 32301014 Review.
20. Kalachand RD, Stordal B, Madden S, Chandler B, Cunningham J, Goode EL, Ruscito I, Braicu EI, Sehouli J, Ignatov A, Yu H, Katsaros D, Mills GB, Lu KH, Carey MS, Timms KM, Kupryjanczyk J, Rzepecka IK, Podgorska A, McAlpine JN, Swisher EM, Bernards SS, O'Riain C, O'Toole S, O'Leary JJ, Bowtell DD, Thomas DM, Prieske K, Joosse SA, Woelber L, Chaudhry P, Häfner N, Runnebaum IB, Hennessy BT. **BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis.** J Natl Cancer Inst. 2020 Dec 14;112(12):1190-1203. doi: 10.1093/jnci/djaa070. PMID: 32413141. Review. PMCID: PMC7735770.
21. Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. **Corrigendum to 'Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer' [EBioMedicine 38 (2018) 100-112].** EBioMedicine. 2020 Feb;52:102630. doi: 10.1016/j.ebiom.2020.102630. Epub 2020 Jan 20. PMID: 31972470. PMCID: PMC6974767.
22. Kim H, Xu H, George E, Hallberg D, Kumar S, Jagannathan V, Medvedev S, Kinose Y, Devins K, Verma P, Ly K, Wang Y, Greenberg RA, Schwartz L, Johnson N, Scharpf RB, Mills GB, Zhang R, Velculescu VE, Brown EJ, Simpkins F. **Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.** Nat Commun. 2020 Jul 24;11(1):3726. doi: 10.1038/s41467-020-17127-2. PMID: 32709856. PMCID: PMC7381609.
23. Kim MS, Ma S, Chelariu-Raicu A, Leuschner C, Alila HW, Lee S, Coleman RL, Sood AK. **Enhanced immunotherapy with LHRH-R targeted lytic peptide in ovarian cancer.** Mol Cancer Ther. 2020 Sep 17;molcanther.0030.2020. doi: 10.1158/1535-7163.MCT-20-0030. PMID: 32943548.
24. Kim O, Park EY, Klinkebiel DL, Pack SD, Shin YH, Abdullaev Z, Emerson RE, Coffey DM, Kwon SY, Creighton CJ, Kwon S, Chang EC, Chiang T, Yatsenko AN, Chien J, Cheon DJ, Yang-Hartwich Y, Nakshatri H, Nephew KP, Behringer RR, Fernández FM, Cho CH, Vanderhyden B, Drapkin R, Bast RC Jr, Miller KD, Karpf AR, Kim J. **In vivo modeling of metastatic human high-grade serous ovarian**

- cancer in mice.** PLoS Genet. 2020 Jun 4;16(6):e1008808. doi: 10.1371/journal.pgen.1008808. eCollection 2020 Jun. PMID: 32497036. PMCID: PMC7297383.
25. Kim O, Park EY, Kwon SY, Shin S, Emerson RE, Shin YH, DeMayo FJ, Lydon JP, Coffey DM, Hawkins SM, Quilliam LA, Cheon DJ, Fernández FM, Nephew KP, Karpf AR, Widschwendter M, Sood AK, Bast RC Jr, Godwin AK, Miller KD, Cho CH, Kim J. **Targeting progesterone signaling prevents metastatic ovarian cancer.** Proc Natl Acad Sci U S A. 2020 Dec 15;117(50):31993-32004. doi: 10.1073/pnas.2013595117. Epub 2020 Dec 1. PMID: 33262282. PMCID: PMC7749341.
26. Kobayashi M, Katayama H, Irajizad E, Vykoukal JV, Fahrman JF, Kundnani DL, Yu CY, Cai Y, Hsiao FC, Yang WL, Lu Z, Celestino J, Long JP, Do KA, Lu KH, Ladd JJ, Urban N, Bast RC Jr, Hanash SM. **Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis.** Cancers (Basel). 2020 Feb 19;12(2):485. doi: 10.3390/cancers12020485. PMID: 32092936. PMCID: PMC7072578.
27. Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM. **Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.** J Clin Oncol. 2020 Apr 10;38(11):1222-1245. doi: 10.1200/JCO.19.02960. Epub 2020 Jan 27. PMID: 31986064.
28. Kurnit KC, Avila M, Hinchcliff EM, Coleman RL, Westin SN. **PARP inhibition in the ovarian cancer patient: Current approvals and future directions.** Pharmacol Ther. 2020 Sep;213:107588. doi: 10.1016/j.pharmthera.2020.107588. Epub 2020 May 23. PMID: 32450190 Review. PMCID: PMC8331065.
29. Lara OD, Bayraktar E, Amero P, Ma S, Ivan C, Hu W, Wang Y, Mangala LS, Dutta P, Bhattacharya P, Ashizawa AT, Lopez-Berestein G, Rodriguez-Aguayo C, Sood AK. **Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer.** Oncotarget. 2020 Jul 21;11(29):2819-2833. doi: 10.18632/oncotarget.27667. eCollection 2020 Jul 21. PMID: 32754300. PMCID: PMC7381098.
30. Lawson BC, Euscher ED, Bassett RL, Liu J, Ramalingam P, Zhong Y, Fleming ND, Malpica A. **A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant?** Am J Surg Pathol. 2020 Feb;44(2):206-213. doi: 10.1097/PAS.0000000000001391. PMID: 31651523. PMCID: PMC6954274.
31. Lee EK, Tan-Wasielewski Z, Aghajanian C, Coleman RL, Curtis J, Hirsch MS, Matulonis UA, Cantley LC, Mills GB, Doyle LA, Liu JF. **Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035).** Gynecol Oncol Rep. 2020 Feb 3;32:100546. doi: 10.1016/j.gore.2020.100546. eCollection 2020 May. PMID: 32083163. PMCID: PMC7021536.
32. Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Celestino J, Morgan MB, Nguyen TV, Conrads KA, Rangel KM, Dood RL, Hajek RA, Fawcett GL, Chu RA, Wilson K, Loffredo JL, Viollet C, Jazaeri AA, Dalgard CL, Mao X, Song X, Zhou M, Hood BL, Banskota N, Wilkerson MD, Te J, Soltis AR, Roman K, Dunn A, Cordover D, Eterovic AK, Liu J, Burks JK, Baggerly KA, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Casablanca Y, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. **Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer.** Cell Rep. 2020 Apr 14;31(2):107502. doi: 10.1016/j.celrep.2020.03.066. PMID: 32294438. PMCID: PMC7234854.
33. Li D, Weng S, Zhong C, Tang X, Zhu N, Cheng Y, Xu D, Yuan Y. **Risk of Second Primary Cancers Among Long-Term Survivors of Breast Cancer.** Front Oncol. 2020 Jan 13;9:1426. doi: 10.3389/fonc.2019.01426. eCollection 2019. PMID: 31998630. PMCID: PMC6970432.
34. Li W, Li R, Feng Z, Ning J. **Semiparametric isotonic regression analysis for risk assessment under nested case-control and case-cohort designs.** Stat Methods Med Res. 2020 Aug;29(8):2328-2343. doi: 10.1177/0962280219893389. Epub 2019 Dec 22. PMID: 31868119. PMCID: PMC7306447.
35. Lu KH, Ou GL, Chang HP, Chen WC, Liu SH, Sheen LY. **Safety evaluation of water extract of Gastrodia elata Blume: Genotoxicity and 28-day oral toxicity studies.** Regul Toxicol Pharmacol. 2020 Jul;114:104657. doi: 10.1016/j.yrtph.2020.104657. Epub 2020 Apr 9. PMID: 32278877.

36. Lutgendorf SK, Penedo F, Goodheart MJ, Dahmouh L, Arevalo JMG, Thaker PH, Slavich GM, Sood AK, Cole SW. **Epithelial-mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation.** *Cancer*. 2020 Oct 1;126(19):4407-4413. doi: 10.1002/cncr.33060. Epub 2020 Jul 21. PMID: 32691853. PMCID: PMC7719066.
37. Lyu T, Jiang Y, Jia N, Che X, Li Q, Yu Y, Hua K, Bast RC Jr, Feng W. **SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.** *Int J Cancer*. 2020 Mar 15;146(6):1553-1567. doi: 10.1002/ijc.32673. Epub 2019 Oct 30. PMID: 31503345.
38. Maoz A, Matsuo K, Ciccone MA, Matsuzaki S, Klar M, Roman LD, Sood AK, Gershenson DM. **Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord-Stromal Tumors: A Contemporary Review.** *Cancers (Basel)*. 2020 May 29;12(6):1398. doi: 10.3390/cancers12061398. PMID: 32485873. Review. PMCID: PMC7353025.
39. Matsuo K, Chang EJ, Matsuzaki S, Mandelbaum RS, Matsushima K, Grubbs BH, Klar M, Roman LD, Sood AK, Wright JD. **Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes.** *Gynecol Oncol*. 2020 Jul;158(1):59-65. doi: 10.1016/j.ygyno.2020.04.045. Epub 2020 May 10. PMID: 32402635. PMCID: PMC7526044.
40. Matsuo K, Huang Y, Matsuzaki S, Klar M, Roman LD, Sood AK, Wright JD. **Minimally Invasive Surgery and Risk of Capsule Rupture for Women With Early-Stage Ovarian Cancer.** *JAMA Oncol*. 2020 Jul 1;6(7):1110-1113. doi: 10.1001/jamaoncol.2020.1702. PMID: 32525512. PMCID: PMC7290694.
41. Matsuo K, Machida H, Grubbs BH, Matsuzaki S, Klar M, Roman LD, Sood AK, Gershenson DM. **Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.** *Gynecol Oncol*. 2020 Apr;157(1):21-28. doi: 10.1016/j.ygyno.2019.08.030. Epub 2020 Jan 15. PMID: 31954535. PMCID: PMC7537352.
42. Matsuo K, Machida H, Matsuzaki S, Grubbs BH, Klar M, Roman LD, Sood AK, Gershenson DM, Wright JD. **Evolving population-based statistics for rare epithelial ovarian cancers.** *Gynecol Oncol*. 2020 Apr;157(1):3-11. doi: 10.1016/j.ygyno.2019.11.122. Epub 2020 Jan 15. PMID: 31954534. PMCID: PMC7526050.
43. Miyake TM, Pradeep S, Bayraktar E, Stur E, Handley KF, Wu SY, Rodriguez-Aguayo C, Lee JS, Lopez-Berestein G, Coleman RL, Sood AK. **NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors.** *Mol Cancer Ther*. 2020 Aug;19(8):1727-1735. doi: 10.1158/1535-7163.MCT-19-0977. Epub 2020 Jun 4. PMID: 32499298. PMCID: PMC7415525.
44. Myers AP, Konstantinopoulos PA, Barry WT, Luo W, Broaddus RR, Makker V, Drapkin R, Liu J, Doyle A, Horowitz NS, Meric-Bernstam F, Birrer M, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN. **Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.** *Int J Cancer*. 2020 Jul 15;147(2):413-422. doi: 10.1002/ijc.32783. Epub 2019 Dec 13. PMID: 31714586. Clinical Trial. PMCID: PMC7214201.
45. Naffar-Abu Amara S, Kuiken HJ, Selfors LM, Butler T, Leung ML, Leung CT, Kuhn EP, Kolarova T, Hage C, Ganesh K, Panayiotou R, Foster R, Rueda BR, Aktipis A, Spellman P, Ince TA, Xiu J, Oberley M, Gatalica Z, Navin N, Mills GB, Bronson RT, Brugge JS. **Transient commensal clonal interactions can drive tumor metastasis.** *Nat Commun*. 2020 Nov 16;11(1):5799. doi: 10.1038/s41467-020-19584-1. PMID: 33199705. PMCID: PMC7669858.
46. Nusbaum DJ, Mandelbaum RS, Machida H, Matsuzaki S, Roman LD, Sood AK, Gershenson DM, Matsuo K. **Significance of lymph node ratio on survival of women with borderline ovarian tumors.** *Arch Gynecol Obstet*. 2020 May;301(5):1289-1298. doi: 10.1007/s00404-020-05535-0. Epub 2020 Apr 17. PMID: 32303888. PMCID: PMC7523228.
47. Oncul S, Amero P, Rodriguez-Aguayo C, Calin GA, Sood AK, Lopez-Berestein G. **Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum.** *RNA Biol*. 2020 Nov;17(11):1523-1534. doi: 10.1080/15476286.2019.1702283. Epub 2019 Dec 17. PMID: 31847695. PMCID: PMC7567512.

48. Onstad M, Coleman RL, Westin SN. **Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.** *Drugs*. 2020 Oct;80(15):1525-1535. doi: 10.1007/s40265-020-01382-0. PMID: 32852746 Review. PMCID: PMC7541632.
49. Parashar D, Nair B, Geethadevi A, George J, Nair A, Tsaih SW, Kadamberi IP, Gopinadhan Nair GK, Lu Y, Ramchandran R, Uyar DS, Rader JS, Ram PT, Mills GB, Pradeep S, Chaluvally-Raghavan P. **Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling.** *Cancer Res*. 2020 Dec 15;80(24):5554-5568. doi: 10.1158/0008-5472.CAN-19-3717. Epub 2020 Oct 21. PMID: 33087324. PMCID: PMC7744365.
50. Peres LC, Sinha S, Townsend MK, Fridley BL, Karlan BY, Lutgendorf SK, Shinn E, Sood AK, Tworoger SS. **Predictors of survival trajectories among women with epithelial ovarian cancer.** *Gynecol Oncol*. 2020 Feb;156(2):459-466. doi: 10.1016/j.ygyno.2019.12.011. Epub 2019 Dec 12. PMID: 31839342. PMCID: PMC7771334.
51. Rao L, Mak VCY, Zhou Y, Zhang D, Li X, Fung CCY, Sharma R, Gu C, Lu Y, Tipoe GL, Cheung ANY, Mills GB, Cheung LWT. **p85 $\beta$  regulates autophagic degradation of AXL to activate oncogenic signaling.** *Nat Commun*. 2020 May 8;11(1):2291. doi: 10.1038/s41467-020-16061-7. PMID: 32385243. PMCID: PMC7210311.
52. Saha B, Mathur T, Handley KF, Hu W, Afshar-Kharghan V, Sood AK, Jain A. **OvCa-Chip microsystem recreates vascular endothelium-mediated platelet extravasation in ovarian cancer.** *Blood Adv*. 2020 Jul 28;4(14):3329-3342. doi: 10.1182/bloodadvances.2020001632. PMID: 32717032. PMCID: PMC7391144.
53. Salem A, Pinto K, Koch M, Liu J, Silva EG. **Are polyploid giant cancer cells in high grade serous carcinoma of the ovary blastomere-like cancer stem cells?** *Ann Diagn Pathol*. 2020 Jun;46:151505. doi: 10.1016/j.anndiagpath.2020.151505. Epub 2020 Mar 18. PMID: 32387856 Review.
54. Santiago-O'Farrill JM, Weroha SJ, Hou X, Oberg AL, Heinzen EP, Maurer MJ, Pang L, Rask P, Amaravadi RK, Becker SE, Romero I, Rubio MJ, Matias-Guiu X, Santacana M, Llombart-Cussac A, Poveda A, Lu Z, Bast RC Jr. **Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.** *Cancer*. 2020 Feb 15;126(4):894-907. doi: 10.1002/cncr.32600. Epub 2019 Nov 12. PMID: 31714594. PMCID: PMC6992526.
55. Sasaki N, Iwaya T, Chiba T, Fujita M, Ju Z, Endo F, Yaegashi M, Hachiya T, Sugimoto R, Sugai T, Siwak DR, Liotta LA, Lu Y, Mills GB, Nakagawa H, Nishizuka SS. **Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA.** *PLoS One*. 2020 Oct 7;15(10):e0239966. doi: 10.1371/journal.pone.0239966. eCollection 2020. PMID: 33027286. PMCID: PMC7540850.
56. Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun CC, Ludemann J, Cooney GA, Coleman R, Sood AK, Mahdi H, Wong KK, Covens A, O'Malley DM, Lecuru F, Cobb LP, Caputo TA, May T, Huang M, Siemon J, Fernández ML, Ray-Coquard I, Gershenson DM. **Low-grade serous ovarian cancer: State of the science.** *Gynecol Oncol*. 2020 Mar;156(3):715-725. doi: 10.1016/j.ygyno.2019.12.033. Epub 2020 Jan 20. PMID: 31969252 Review.
57. Sun C, Li X, Guo E, Li N, Zhou B, Lu H, Huang J, Xia M, Shan W, Wang B, Li K, Weng D, Xu X, Gao Q, Wang S, Hu J, Lu Y, Mills GB, Chen G. **MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis.** *Oncogene*. 2020 Feb;39(8):1681-1695. doi: 10.1038/s41388-019-1090-1. Epub 2019 Nov 8. PMID: 31705064. PMCID: PMC8290627.
58. Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC. **PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.** *J Clin Oncol*. 2020 Oct 20;38(30):3468-3493. doi: 10.1200/JCO.20.01924. Epub 2020 Aug 13. PMID: 32790492.
59. Tuna M, Ju Z, Yoshihara K, Amos CI, Tanyi JL, Mills GB. **Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers.** *Br J Cancer*. 2020 Feb;122(3):405-412. doi: 10.1038/s41416-019-0654-8. Epub 2019 Nov 29. PMID: 31780779. PMCID: PMC7000721.

60. Xiong C, Wen Y, Zhao J, Yin D, Xu L, Chelariu-Raicu A, Yao C, Leng X, Liu J, Chaudhari RR, Zhang S, Sood AK, Li C. **Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions.** *Sci Rep.* 2020 Jan 16;10(1):520. doi: 10.1038/s41598-020-57477-x. PMID: 31949258. PMCID: PMC6965176.
61. Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC Jr. **Correction: Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.** *Clin Cancer Res.* 2020 Sep 15;26(18):5050. doi: 10.1158/1078-0432.CCR-20-3198. PMID: 32934031.
62. Yang M, Liu Q, Huang T, Tan W, Qu L, Chen T, Pan H, Chen L, Liu J, Wong CW, Lu WW, Guan M. **Dysfunction of estrogen-related receptor alpha-dependent hepatic VLDL secretion contributes to sex disparity in NAFLD/NASH development.** *Theranostics.* 2020 Aug 29;10(24):10874-10891. doi: 10.7150/thno.47037. eCollection 2020. PMID: 33042259. PMCID: PMC7532682.
63. Yang WL, Lu Z, Guo J, Fellman BM, Ning J, Lu KH, Menon U, Kobayashi M, Hanash SM, Celestino J, Skates SJ, Bast RC Jr. **Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer.** *Cancer.* 2020 Feb 15;126(4):725-736. doi: 10.1002/cncr.32582. Epub 2019 Nov 12. PMID: 31714597. PMCID: PMC6992519.
64. Zibetti Dal Molin G, Westin SN, Msaouel P, Gomes LM, Dickens A, Coleman RL. **Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors.** *Int J Gynecol Cancer.* 2020 Jan;30(1):89-93. doi: 10.1136/ijgc-2019-000714. Epub 2019 Dec 1. PMID: 31792084.